Antiphospholipid Syndrome and Endothelial Injury: Unraveling the Links with Complement Hyperactivation and Thrombotic Microangiopathy in Severe COVID-19
Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(25)00257-7/abstract Related to the article: " SARS-CoV-2 enhances complement-mediated endothelial injury via suppression of membrane complement regulatory proteins" https://www.tandfonline.com/doi/full/10.1080/22221751.2025.2467781#abstract Introduction Antiphospholipid syndrome (APS) is an autoimmune disorder that falls within the broader spectrum of conditions such as systemic lupus erythematosus (SLE), systemic sclerosis, myositis, and primary immune thrombocytopenia (ITP). Promising therapeutic approaches are also emerging in diseases like myasthenia gravis. APS is characterized by the presence of antiphospholipid antibodies (aPLs), which contribute to thro...